Fusaric acid: a novel agent and mechanism to treat HNSCC.
Publication/Presentation Date
7-1-2004
Abstract
OBJECTIVE: A new class of carboxylic acids has tumoricidal activity for head and neck squamous cell cancer (HNSCC). Fusaric acid (FA) can chelate divalent cations, especially zinc, and inactivate zinc finger proteins involved in DNA repair and protein synthesis.
METHODS: 2 squamous carcinoma lines were utilized for in vitro and in vivo portions of this study. Cell counting and flow cytometry were used to analyze cells in culture in treatment and control groups over 96 hours. HNSCC subcutaneous implants were created in treatment and control groups of BALB-c nude mice (N = 30).
RESULTS: In vitro studies demonstrated significant changes in cell numbers and cell cycle. In vivo studies of daily intralesional therapy for 1 month also showed reduced onset of growth and overall growth compared to controls.
CONCLUSION: FA appears to have a tumoristatic/tumoricidal effect on HNSCC. Further nude mice studies are needed to optimize dosing and administration regimens for FA in anticipation of clinical trials.
Volume
131
Issue
1
First Page
54
Last Page
60
ISSN
0194-5998
Published In/Presented At
Stack, B. C., Jr, Hansen, J. P., Ruda, J. M., Jaglowski, J., Shvidler, J., & Hollenbeak, C. S. (2004). Fusaric acid: a novel agent and mechanism to treat HNSCC. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 131(1), 54–60. https://doi.org/10.1016/j.otohns.2004.02.038
Disciplines
Community Health and Preventive Medicine | Health Services Research | Medicine and Health Sciences
PubMedID
15243558
Department(s)
Department of Community Health and Health Studies
Document Type
Article